The
U.S. Patent and Trademark Office issued an identification number for
Cellectar Biosciences Inc.'s (Nasdaq: CLRB) application for Phospholipid-Ether
Analogs as Cancer Targeting Drug Vehicles. Shares of the biopharmaceutical leaped $2.37 to $3.42.
Cellectar Biosciences receives patent ID#
May 20, 2016 at 13:36 PM EDT